In the Relapsing-Remitting form of Multiple Sclerosis (RRMS), a single biomarker (soluble neurofilament light chain or sNfL) is identified as a biomarker for inflammatory activity in MS, but is limited in its ability to identify relapses. Through screening several hundred proteins using Olink ® technology, three additional protein biomarkers have been identified as an improved relapse-specific signature to monitor disease activity in RRMS patients.